» Articles » PMID: 34602936

The Pathogenesis of COVID-19-induced IgA Nephropathy and IgA Vasculitis: A Systematic Review

Overview
Specialty General Medicine
Date 2021 Oct 4
PMID 34602936
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: IgA nephropathy (IgAN) and IgA vasculitis (IgAV) are part of a similar clinical spectrum. Both clinical conditions occur with the coronavirus disease 2019 (COVID-19). This review aims to recognize the novel association of IgAN and IgAV with COVID-19 and describe its underlying pathogenesis.

Methods: We conducted a systematic literature search and data extraction from PubMed, Cochrane, ScienceDirect, and Google Scholar following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.

Results: Our search identified 13 cases reporting IgAV and IgAN associated with COVID-19 infection and 4 cases of IgAN following COVID-19 vaccination. The mean, mode, and median ages of patients were 23.8, 4, and 8 years, respectively. Most cases associated with COVID-19 infection were reported in males (77%). Rash and purpura (85%) were the most common clinical features, followed by gastrointestinal symptoms (62%). In symptomatic cases, skin or renal biopsy and immunofluorescence confirmed the diagnosis of IgAN or IgAV. Most patients were treated with steroids and reported recovery or improvement; however, death was reported in two patients.

Conclusion: There is a paucity of scientific evidence on the pathogenesis of the association of IgAN and IgAV with COVID-19, which thus needs further study. Current research suggests the role of IgA-mediated immune response, evidenced by early seroconversion to IgA in COVID-19 patients and the role of IgA in immune hyperactivation as the predominant mediator of the disease process. Clinicians, especially nephrologists and paediatricians, need to recognize this association, as this disease is usually self-limited and can lead to complete recovery if prompt diagnosis and treatment are provided.

Citing Articles

Incidence and pathological features of IgA nephropathy before and during the COVID-19 pandemic.

Liu W, Xu R, Wu D, Su Z, Cheng Y, Hu H Sci Rep. 2025; 15(1):4656.

PMID: 39920226 PMC: 11806036. DOI: 10.1038/s41598-025-89170-2.


The Impact of Infectious Diseases on Clinical Characteristics and Immunological Correlations in Pediatric Henoch-Schönlein Purpura: A Five-Year Retrospective Study.

Opritescu S, Nitescu G, Golumbeanu M, Boghitoiu D, Ionita E, Usurelu D Biomedicines. 2025; 13(1).

PMID: 39857697 PMC: 11762163. DOI: 10.3390/biomedicines13010113.


The influence of respiratory infections on Henoch-Schönlein purpura in children.

Wang B, Xiang W, Zhu Z, Shen H BMC Infect Dis. 2025; 25(1):118.

PMID: 39856587 PMC: 11763152. DOI: 10.1186/s12879-025-10514-4.


Clinical characteristics and risk factors analysis of abdominal symptoms in IgA vasculitis patients: a retrospective cohort study.

Gu Y, Zhang Y, Zheng Z, Zhu P Clin Rheumatol. 2024; 44(1):349-356.

PMID: 39510986 DOI: 10.1007/s10067-024-07226-6.


SARS-CoV-2 as a trigger of IgA vasculitis: a clinical case and literature review.

Auanassova A, Yessirkepov M, Kocyigit B Rheumatol Int. 2024; 44(11):2613-2620.

PMID: 39249140 DOI: 10.1007/s00296-024-05712-3.


References
1.
Li N, Papini A, Shao T, Girard L . Immunoglobulin-A Vasculitis With Renal Involvement in a Patient With COVID-19: A Case Report and Review of Acute Kidney Injury Related to SARS-CoV-2. Can J Kidney Health Dis. 2021; 8:2054358121991684. PMC: 7868447. DOI: 10.1177/2054358121991684. View

2.
Mandai S, Aoyagi M, Nagahama K, Arai Y, Hirasawa S, Aki S . Post-staphylococcal infection Henoch-Schönlein purpura nephritis: a case report and review of the literature. Ren Fail. 2013; 35(6):869-74. DOI: 10.3109/0886022X.2013.794703. View

3.
Reamy B, Williams P, Lindsay T . Henoch-Schönlein purpura. Am Fam Physician. 2009; 80(7):697-704. View

4.
Suzuki H . Biomarkers for IgA nephropathy on the basis of multi-hit pathogenesis. Clin Exp Nephrol. 2018; 23(1):26-31. PMC: 6344607. DOI: 10.1007/s10157-018-1582-2. View

5.
Roberts K, Colley L, Agbaedeng T, Ellison-Hughes G, Ross M . Vascular Manifestations of COVID-19 - Thromboembolism and Microvascular Dysfunction. Front Cardiovasc Med. 2020; 7:598400. PMC: 7649150. DOI: 10.3389/fcvm.2020.598400. View